#AAD24 roundup: Data from Sanofi, Alumis, Galderma and more

Below are notable updates from the American Academy of Dermatology’s annual meeting over the weekend:

Sanofi amends trial protocol

Sanofi has big plans for amlitelimab, the monoclonal antibody that binds to OX40-Ligand acquired in the $1.5 billion Kymab bolt-on from 2021. But first up is atopic dermatitis.